Most practices choose a Tuesday or Thursday lunch slot. Reschedule any time.
Reserve your time →Overmedication is not a fringe concern — it's a common preventable harm in American healthcare. Adverse drug events (ADEs) send more than 1.5 million people to U.S. emergency departments every year. [1] The CDC defines an ADE as harm caused by a medication, including allergic reactions, side effects, medication errors, and overmedication itself. [1]
The problem compounds with the number of medications a patient is taking. Polypharmacy, generally defined as five or more medications daily, affects 37% of the general population and 65% of adults over 65. [2] In long-term care settings, the burden climbs further: one analysis found that up to 74% of patients in skilled nursing facilities take nine or more medications. [3] A widely cited rule of thumb holds that patients taking five medications will, on average, experience at least one significant drug-related problem. [3]
Fixed-dose combination products and standard weight-based protocols are convenient, but literature shows that uniform dosing does not fit every patient equally well. [7] Because metabolism, body composition, and comorbidities vary widely, a dose calibrated for an average patient can be too high for some and too low for others, increasing the risk of side effects without necessarily improving efficacy.
The evidence for individualized titration is strong. In a growth hormone study, patients who received individualized dose titration achieved similar efficacy to those on a fixed weight-based protocol, but experienced side effects at a rate of only 30%, compared with 70% in the fixed-dose group. [8] Titration guidance embedded in clinical protocols has likewise been shown to reduce the incidence of adverse drug reactions, [9] and current ADHD treatment guidelines recommend individualized dose optimization over one-size-fits-all fixed dosing. [10]
Individualized titration achieved similar efficacy to fixed weight-based dosing — with side effects in 30% of patients, compared with 70% on the fixed-dose protocol.
Not every Flex Dosing product addresses this gap the same way — and that’s by design. The Flex Dosing portfolio takes several distinct approaches to the dosing and adherence challenges outlined above, matched to what each therapy and patient population actually needs.
Where a molecule can be dosed more than one way, Flex Dosing carries more than one strength of it. Fenoprofen calcium is available as Fenopron™ 300 mg alongside a 200 mg capsule. Tolmetin sodium comes as 400 mg tablets and as Tolectin® 600 at 600 mg. That gives a prescriber room to step a patient up or down within the same molecule, and to reach a therapeutic daily dose in fewer tablets, rather than settling for the nearest strength the market happens to stock.
The dermatology range covers antipruritics and topical corticosteroids across the potency spectrum. Crotan (crotamiton 10%) Lotion treats pruritus directly, in an 8 fl oz bottle. The corticosteroids run from Hydrocortisone Lotion 2% and Hydrocortisone Acetate Cream 2.5% at the low-potency end, through Halog® (halcinonide) 0.1%, up to Ultravate® — halobetasol propionate lotion 0.05% — at the high-potency end. Vehicle matters as much as potency in dermatology, so halcinonide 0.1% is offered as both a 60 g cream and a 120 mL topical solution, letting the format follow the treatment site.
Some of these strengths sit where the conventional steps do not. Metformin HCl is offered at 625 mg and 750 mg — increments between the usual dosing steps — and Relgaabi (gabapentin) is stocked as a 200 mg capsule, between the commonly dispensed 100 mg and 300 mg. Where no tablet divides finely enough, liquids do the work instead: Clemastine Fumarate Syrup at 0.5 mg/5 mL.
The common thread across all three is range. Where a molecule is offered in more than one strength, a prescriber can choose the one that fits rather than the nearest available step. Where the treatment site or the patient makes a tablet impractical, a lotion, solution or suspension can take its place. Which approach applies depends on the therapy — but the goal is the same: fewer patients over- or under-dosed, or carrying more pills than they need, simply because the available product did not match what they actually required.
Or call (210) 460-2085
This content is intended for healthcare professionals. It is educational in nature and does not constitute clinical guidance for any individual patient. Prescribing decisions should always be based on full product labeling and individual patient assessment.
Lunch & Learn
Pick a time that suits your practice